Norinchukin Bank The grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,122 shares of the medical research company’s stock after buying an additional 3,535 shares during the period. Norinchukin Bank The’s holdings in Amgen were worth $16,542,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in AMGN. Baker Ellis Asset Management LLC bought a new position in Amgen in the 3rd quarter worth about $108,000. Phocas Financial Corp. bought a new position in Amgen in the 2nd quarter worth about $110,000. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Amgen by 110.7% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock worth $113,000 after purchasing an additional 340 shares in the last quarter. Taylor Hoffman Wealth Management bought a new position in Amgen in the 4th quarter worth about $127,000. Finally, Salem Investment Counselors Inc. boosted its stake in Amgen by 4.7% in the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 79.53% of the company’s stock.
A number of brokerages recently issued reports on AMGN. Mizuho upped their price target on shares of Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, February 12th. Leerink Swann reiterated a “market perform” rating on shares of Amgen in a research note on Friday, February 2nd. Morgan Stanley dropped their price target on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a research note on Friday, February 2nd. BMO Capital Markets upped their price target on shares of Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research note on Friday, February 2nd. Finally, JPMorgan Chase reiterated a “hold” rating and issued a $191.00 price target on shares of Amgen in a research note on Sunday, February 4th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and an average target price of $190.57.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 4,575 shares of company stock valued at $838,064 in the last ninety days. Insiders own 0.19% of the company’s stock.
NASDAQ AMGN opened at $168.14 on Friday. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23. The stock has a market cap of $123,936.70, a PE ratio of 13.67, a price-to-earnings-growth ratio of 2.11 and a beta of 1.36. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. During the same period in the previous year, the company earned $2.89 EPS. Amgen’s revenue for the quarter was down 2.7% compared to the same quarter last year. sell-side analysts forecast that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s payout ratio is currently 41.97%.
Amgen announced that its board has initiated a stock buyback program on Thursday, February 1st that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/norinchukin-bank-the-increases-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.